# Rafa Laboratories awarded $45M follow-on production agreement from U.S. DoD

Rafa Laboratories Ltd. was awarded a follow-on production agreement valued at over $45 million from the U.S. Department of Defense's JPEO-CBRND for the Midazolam Injection autoinjector (Advanced Anticonvulsant System). Deliveries began in December 2022.

- Type: Contract
- Announced: 2023-02-23
- Where: United States
- Value: $45.0M
- Status: completed
- Products: Midazolam Injection autoinjector (Advanced Anticonvulsant System)
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Rafa Laboratories](https://endata.com/companies/68756.md)
- [U.S. Department of Defense](https://endata.com/companies/4836.md) (customer)

## Sources

- [prnewswire.com](https://www.prnewswire.com/news-releases/us-department-of-defense-awards-rafa-laboratories-production-follow-on-agreement-of-over-45-million-301754175.html), 2023-02-23: "Rafa was awarded a follow-on production agreement for a total value of over $45 million (W911SR2390004) from the Defense Department’s (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND)."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.